SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes | Aplastic Anemia and MDS International Foundation

SOHO State of the Art Update and Next Questions: Biology and Treatment of Myelodysplastic Syndromes

Journal Title: 
Clin Lymphoma Myeloma Leuk
Primary Author: 
Sallman DA
Author(s): 
Sallman DA, Tanaka TN, List A, Bejar R
Original Publication Date: 
Sunday, October 1, 2017

Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms characterized by clonal hematopoiesis leading to bone marrow dysplasia and cytopenias. Recently, significant advancements have been made in understanding the pathogenic mechanisms of this disease. In particular, how a wide array of somatic mutations can induce a common clinical phenotype has been investigated. Specifically, activation of innate immune signaling (i.e. myeloid derived suppressor cells) and the NLRP3 inflammasome in hematopoietic stem/progenitor cells play a central role in the biology of MDS, leading to pyroptotic cell death and clonal expansion. Additionally, deciphering the molecular drivers of MDS using next-generation sequencing has rapidly expanded our understanding of MDS with profound implications for prognosis, treatment decisions, and future clinical investigations. Together, unraveling of the role of innate immunity/pyroptosis in the clinical phenotype of MDS patients and comprehensive molecular characterization has identified novel therapeutic strategies that offer significant promise.

Bone Marrow Diseases: